Novavax, Inc. (NVAX) Down 1.79% in Premarket Trading

Novavax, Inc. (NVAX) is lower by Monday morning, with the stock losing -1.79% in pre-market trading to 157.6. NVAX's short-term technical score of 35 indicates that the stock has traded less bullishly over the last month than 65% of stocks on the market. In the Biotechnology industry, which ranks 139 out of 146 industries, NVAX ranks higher than 61% of stocks. Novavax, Inc. has risen 0.81% over the past month, closing at $173.02 on November 8. During this period of time, the stock fell as low as $160.48 and as high as $229.00. NVAX has an average analyst recommendation of Strong Buy. The company has an average price target of $260.60.

NVAX has an Overall Score of 41. Find out what this means to you and get the rest of the rankings on NVAX!

See Full NVAX Report

Novavax, Inc. has a Long-Term Technical rank of 29. This means that trading over the last 200 trading days has placed the company in the lower half of stocks with 71% of the market scoring higher. In the Biotechnology industry which is number 140 by this metric, NVAX ranks better than 61% of stocks.

Important Dates for Investors in NVAX:

-Novavax, Inc. is set to release earnings on 2/2/2022. During their last earnings release the company posted EPS of $-14.99. -We do not have a set dividend date for Novavax, Inc. at this time. Click Here To Get The Full Report on Novavax, Inc. (NVAX)